FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285257143> ?p ?o ?g. }

• W4285257143 endingPage "841" @default.
• W4285257143 startingPage "834" @default.
• W4285257143 abstract "Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan. Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635). Results: The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263-0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021). Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge." @default.
• W4285257143 created "2022-07-14" @default.
• W4285257143 creator A5000539432 @default.
• W4285257143 creator A5001203362 @default.
• W4285257143 creator A5002355533 @default.
• W4285257143 creator A5002371712 @default.
• W4285257143 creator A5004672828 @default.
• W4285257143 creator A5007908299 @default.
• W4285257143 creator A5010538578 @default.
• W4285257143 creator A5011170655 @default.
• W4285257143 creator A5011282890 @default.
• W4285257143 creator A5014511011 @default.
• W4285257143 creator A5015290458 @default.
• W4285257143 creator A5022236471 @default.
• W4285257143 creator A5022557754 @default.
• W4285257143 creator A5023374305 @default.
• W4285257143 creator A5025098084 @default.
• W4285257143 creator A5025166622 @default.
• W4285257143 creator A5025206301 @default.
• W4285257143 creator A5025321734 @default.
• W4285257143 creator A5029341685 @default.
• W4285257143 creator A5029758586 @default.
• W4285257143 creator A5036104845 @default.
• W4285257143 creator A5043717227 @default.
• W4285257143 creator A5045681141 @default.
• W4285257143 creator A5046703084 @default.
• W4285257143 creator A5049157637 @default.
• W4285257143 creator A5050752720 @default.
• W4285257143 creator A5052804975 @default.
• W4285257143 creator A5053354766 @default.
• W4285257143 creator A5055928124 @default.
• W4285257143 creator A5060110200 @default.
• W4285257143 creator A5062213262 @default.
• W4285257143 creator A5062742683 @default.
• W4285257143 creator A5063206717 @default.
• W4285257143 creator A5064024933 @default.
• W4285257143 creator A5066218416 @default.
• W4285257143 creator A5067425086 @default.
• W4285257143 creator A5068188890 @default.
• W4285257143 creator A5070478370 @default.
• W4285257143 creator A5073478620 @default.
• W4285257143 creator A5074645951 @default.
• W4285257143 creator A5075429460 @default.
• W4285257143 creator A5079656278 @default.
• W4285257143 creator A5080290598 @default.
• W4285257143 creator A5081837886 @default.
• W4285257143 creator A5083652023 @default.
• W4285257143 creator A5085946930 @default.
• W4285257143 creator A5087435965 @default.
• W4285257143 creator A5087783363 @default.
• W4285257143 creator A5046731506 @default.
• W4285257143 date "2022-01-01" @default.
• W4285257143 modified "2023-09-26" @default.
• W4285257143 title "Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic" @default.
• W4285257143 cites W2111635289 @default.
• W4285257143 cites W3034548712 @default.
• W4285257143 cites W3039901154 @default.
• W4285257143 cites W3046463683 @default.
• W4285257143 cites W3111255098 @default.
• W4285257143 cites W3111431752 @default.
• W4285257143 cites W3125712166 @default.
• W4285257143 cites W3130984893 @default.
• W4285257143 cites W3133980772 @default.
• W4285257143 cites W3155123963 @default.
• W4285257143 cites W3157162195 @default.
• W4285257143 cites W3170733499 @default.
• W4285257143 cites W3174632378 @default.
• W4285257143 cites W3179237938 @default.
• W4285257143 cites W3182094313 @default.
• W4285257143 cites W3184169211 @default.
• W4285257143 cites W3184226105 @default.
• W4285257143 cites W3194649867 @default.
• W4285257143 cites W3195596295 @default.
• W4285257143 cites W3198860035 @default.
• W4285257143 cites W3210875779 @default.
• W4285257143 cites W4226087910 @default.
• W4285257143 doi "https://doi.org/10.7150/ijms.71132" @default.
• W4285257143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35693744" @default.
• W4285257143 hasPublicationYear "2022" @default.
• W4285257143 type Work @default.
• W4285257143 citedByCount "4" @default.
• W4285257143 countsByYear W42852571432022 @default.
• W4285257143 countsByYear W42852571432023 @default.
• W4285257143 crossrefType "journal-article" @default.
• W4285257143 hasAuthorship W4285257143A5000539432 @default.
• W4285257143 hasAuthorship W4285257143A5001203362 @default.
• W4285257143 hasAuthorship W4285257143A5002355533 @default.
• W4285257143 hasAuthorship W4285257143A5002371712 @default.
• W4285257143 hasAuthorship W4285257143A5004672828 @default.
• W4285257143 hasAuthorship W4285257143A5007908299 @default.
• W4285257143 hasAuthorship W4285257143A5010538578 @default.
• W4285257143 hasAuthorship W4285257143A5011170655 @default.
• W4285257143 hasAuthorship W4285257143A5011282890 @default.
• W4285257143 hasAuthorship W4285257143A5014511011 @default.
• W4285257143 hasAuthorship W4285257143A5015290458 @default.
• W4285257143 hasAuthorship W4285257143A5022236471 @default.
• W4285257143 hasAuthorship W4285257143A5022557754 @default.
• W4285257143 hasAuthorship W4285257143A5023374305 @default.

• next